Welcome!

News Feed Item

Influenza Global Clinical Trials Review, H2, 2013



 

 

 

LONDON, March 19, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Influenza Global Clinical Trials Review, H2, 2013


Influenza Global Clinical Trials Review, H2, 2013


Summary

GlobalData's clinical trial report, "Influenza Global Clinical Trials Review, H2, 2013" provides data on the Influenza clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Influenza. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Influenza. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)


Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Influenza 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by BRIC Nations 16
Clinical Trials by G7 Nations 17
Clinical Trials in G7 Nations by Trial Status 18
Clinical Trials by E7 Nations 19
Clinical Trials in E7 Nations by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Unaccomplished Trials of Influenza 24
Subjects Recruited Over a Period of Time 31
Prominent Sponsors 32
Top Companies Participating in Influenza Therapeutics Clinical Trials 34
Prominent Drug Comparison 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
GlaxoSmithKline plc 37
Clinical Trial Overview of GlaxoSmithKline plc 37
Novartis AG 49
Clinical Trial Overview of Novartis AG 49
Sanofi 56
Clinical Trial Overview of Sanofi 56
MedImmune, LLC 61
Clinical Trial Overview of MedImmune, LLC 61
F. Hoffmann-La Roche Ltd. 65
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 65
CSL Limited 67
Clinical Trial Overview of CSL Limited 67
Baxter International Inc. 69
Clinical Trial Overview of Baxter International Inc. 69
Daiichi Sankyo Company, Limited 71
Clinical Trial Overview of Daiichi Sankyo Company, Limited 71
Crucell Holland B.V 72
Clinical Trial Overview of Crucell Holland B.V 72
BioCryst Pharmaceuticals, Inc. 73
Clinical Trial Overview of BioCryst Pharmaceuticals, Inc. 73
Adimmune Corporation 74
Clinical Trial Overview of Adimmune Corporation 74
Sinovac Biotech Co., Ltd. 75
Clinical Trial Overview of Sinovac Biotech Co., Ltd. 75
OMNINVEST Vaccine Manufacturing, Researching and Trading Ltd. 76
Clinical Trial Overview of OMNINVEST Vaccine Manufacturing, Researching and Trading Ltd. 76
Novartis Vaccines and Diagnostics, Inc. 77
Clinical Trial Overview of Novartis Vaccines and Diagnostics, Inc. 77
Novavax, Inc. 78
Clinical Trial Overview of Novavax, Inc. 78
VaxInnate Corporation 79
Clinical Trial Overview of VaxInnate Corporation 79
Protein Sciences Corporation 80
Clinical Trial Overview of Protein Sciences Corporation 80
Abbott Laboratories 81
Clinical Trial Overview of Abbott Laboratories 81
Kaketsuken K.K. 82
Clinical Trial Overview of Kaketsuken K.K. 82
Pfizer Inc. 83
Clinical Trial Overview of Pfizer Inc. 83
Clinical Trial Overview of Top Institutes / Government 84
The National Institute of Allergy and Infectious Diseases 84
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 84
The University of Hong Kong 91
Clinical Trial Overview of The University of Hong Kong 91
University of Oxford 92
Clinical Trial Overview of University of Oxford 92
University Hospitals of Leicester NHS Trust 93
Clinical Trial Overview of University Hospitals of Leicester NHS Trust 93
National Hospital Organization Mie National Hospital 94
Clinical Trial Overview of National Hospital Organization Mie National Hospital 94
Centers for Disease Control and Prevention 95
Clinical Trial Overview of Centers for Disease Control and Prevention 95
St. Jude Children's Research Hospital, Inc. 96
Clinical Trial Overview of St. Jude Children's Research Hospital, Inc. 96
The University of British Columbia 97
Clinical Trial Overview of The University of British Columbia 97
University of the Witwatersrand 98
Clinical Trial Overview of University of the Witwatersrand 98
Program for Appropriate Technology in Health 99
Clinical Trial Overview of Program for Appropriate Technology in Health 99
University of Rochester 100
Clinical Trial Overview of University of Rochester 100
Columbia University 101
Clinical Trial Overview of Columbia University 101
Assistance Publique - Hopitaux de Paris 102
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 102
McMaster University 103
Clinical Trial Overview of McMaster University 103
Institut National de la Sante et de la Recherche Medicale 104
Clinical Trial Overview of Institut National de la Sante et de la Recherche Medicale 104
Queen Mary Hospital 105
Clinical Trial Overview of Queen Mary Hospital 105
University of Pittsburgh 106
Clinical Trial Overview of University of Pittsburgh 106
Hadassah Medical Organization 107
Clinical Trial Overview of Hadassah Medical Organization 107
University of Michigan 108
Clinical Trial Overview of University of Michigan 108
University of Alberta 109
Clinical Trial Overview of University of Alberta 109
Five Key Clinical Profiles 110
Appendix 161
Abbreviations 161
Definitions 161
Research Methodology 162
Secondary Research 162
About GlobalData 163
Contact Us 163
Disclaimer 163
Source 164




List of Tables

Influenza Therapeutics Market, Global, Clinical Trials by Zone, 2013* 8
Influenza Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 9
Influenza Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 10
Influenza Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2013* 11
Influenza Therapeutics Clinical Trials, Europe, Top Five Countries, 2013* 12
Influenza Therapeutics Clinical Trials, North America, Top Countries, 2013* 13
Influenza Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2013* 14
Influenza Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2013* 15
Influenza Therapeutics Clinical Trials, BRIC Countries, 2013* 16
Influenza Therapeutics Clinical Trials, G7 Countries, 2013* 17
Influenza Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 18
Influenza Therapeutics Clinical Trials, E7 Countries, 2013* 19
Influenza Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 20
Influenza Therapeutics Market, Global, Clinical Trials by Phase, 2013* 21
Influenza Therapeutics Market, Global, Clinical Trials In Progress by Phase 2013* 22
Influenza Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 23
Influenza Therapeutics Market, Global, Suspended Clinical Trials, 2013* 24
Influenza Therapeutics Market, Global, Withdrawn Clinical Trials, 2013* 25
Influenza Therapeutics Market, Global, Terminated Clinical Trials, 2013* 27
Influenza Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 31
Influenza Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 33
Influenza Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 35
Influenza Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 36
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2013* 37
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2013* 49
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2013* 56
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by MedImmune, LLC, 2013* 61
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2013* 65
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by CSL Limited, 2013* 67
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2013* 69
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2013* 71
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Crucell Holland B.V, 2013* 72
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by BioCryst Pharmaceuticals, Inc., 2013* 73
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Adimmune Corporation, 2013* 74
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Sinovac Biotech Co., Ltd., 2013* 75
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by OMNINVEST Vaccine Manufacturing, Researching and Trading Ltd., 2013* 76
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis Vaccines and Diagnostics, Inc., 2013* 77
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Novavax, Inc., 2013* 78
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by VaxInnate Corporation, 2013* 79
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Protein Sciences Corporation, 2013* 80
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2013* 81
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaketsuken K.K., 2013* 82
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2013* 83
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2013* 84
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Hong Kong, 2013* 91
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2013* 92
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospitals of Leicester NHS Trust, 2013* 93
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by National Hospital Organization Mie National Hospital, 2013* 94
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2013* 95
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by St. Jude Children's Research Hospital, Inc., 2013* 96
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of British Columbia, 2013* 97
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by University of the Witwatersrand, 2013* 98
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Program for Appropriate Technology in Health, 2013* 99
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Rochester, 2013* 100
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2013* 101
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2013* 102
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by McMaster University, 2013* 103
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut National de la Sante et de la Recherche Medicale, 2013* 104
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Queen Mary Hospital, 2013* 105
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2013* 106
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by Hadassah Medical Organization, 2013* 107
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2013* 108
Influenza Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Alberta, 2013* 109

List of Figures
Influenza Therapeutics Market, Global, Clinical Trials by Zone (%), 2013* 8
Influenza Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 9
Influenza Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 10
Influenza Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2013* 11
Influenza Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2013* 12
Influenza Therapeutics Clinical Trials, North America, Top Countries (%), 2013* 13
Influenza Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2013* 14
Influenza Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2013* 15
Influenza Therapeutics Clinical Trials, BRIC Countries (%), 2013* 16
Influenza Therapeutics Clinical Trials, G7 Countries (%), 2013* 17
Influenza Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 18
Influenza Therapeutics Clinical Trials, E7 Countries (%), 2013* 19
Influenza Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 20
Influenza Therapeutics Market, Global, Clinical Trials by Phase (%), 2013* 21
Influenza Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2013* 22
Influenza Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 23
Influenza Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 31
Influenza Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 32
Influenza Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 34
Influenza Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 36
GlobalData Methodology 162


Read the full report:
Influenza Global Clinical Trials Review, H2, 2013
http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trial...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, when the pain caused by the exponential complexity becomes apparent. We've seen this problem occur time and time again. In his session at Big Data Expo, Greg Bruno, Vice President of Engineering and co-founder of StackIQ...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
"Tintri was started in 2008 with the express purpose of building a storage appliance that is ideal for virtualized environments. We support a lot of different hypervisor platforms from VMware to OpenStack to Hyper-V," explained Dan Florea, Director of Product Management at Tintri, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and containers together help companies achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of Dev...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
The security needs of IoT environments require a strong, proven approach to maintain security, trust and privacy in their ecosystem. Assurance and protection of device identity, secure data encryption and authentication are the key security challenges organizations are trying to address when integrating IoT devices. This holds true for IoT applications in a wide range of industries, for example, healthcare, consumer devices, and manufacturing. In his session at @ThingsExpo, Lancen LaChance, vic...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it m...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
In their general session at 16th Cloud Expo, Michael Piccininni, Global Account Manager - Cloud SP at EMC Corporation, and Mike Dietze, Regional Director at Windstream Hosted Solutions, reviewed next generation cloud services, including the Windstream-EMC Tier Storage solutions, and discussed how to increase efficiencies, improve service delivery and enhance corporate cloud solution development. Michael Piccininni is Global Account Manager – Cloud SP at EMC Corporation. He has been engaged in t...
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus o...
Big Data engines are powering a lot of service businesses right now. Data is collected from users from wearable technologies, web behaviors, purchase behavior as well as several arbitrary data points we’d never think of. The demand for faster and bigger engines to crunch and serve up the data to services is growing exponentially. You see a LOT of correlation between “Cloud” and “Big Data” but on Big Data and “Hybrid,” where hybrid hosting is the sanest approach to the Big Data Infrastructure pro...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Hardware virtualization and cloud computing allowed us to increase resource utilization and increase our flexibility to respond to business demand. Docker Containers are the next quantum leap - Are they?! Databases always represented an additional set of challenges unique to running workloads requiring a maximum of I/O, network, CPU resources combined with data locality.